The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity (Q33871868)

29 July 2017

title

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity (English)

1 reference

29 July 2017

Matthew J Fuchter

9

0 references

Anthony G. M. Barrett

16

object named as

Anthony G M Barrett

1 reference

29 July 2017

14

Dennis C Liotta

1 reference

29 July 2017

Eric O Aboagye

15

1 reference

ORCID Public Data File 2021

Sebastian H B Kroll

3

object named as

Sebastian H B Kroll

1 reference

29 July 2017

Manikandan Periyasamy

10

object named as

Manikandan Periyasamy

1 reference

29 July 2017

8

Alekasandra Siwicka

1 reference

29 July 2017

12

Seshu K Kanneganti

1 reference

29 July 2017

5

Bodo Scheiper

1 reference

29 July 2017

7

Jan Brackow

1 reference

29 July 2017

Simak Ali

1

1 reference

29 July 2017

Dean A Heathcote

2

1 reference

29 July 2017

Ashutosh S Jogalekar

4

1 reference

29 July 2017

Hetal Patel

6

1 reference

29 July 2017

Robert S Tolhurst

11

1 reference

29 July 2017

James P Snyder

13

1 reference

29 July 2017

R Charles Coombes

17

1 reference

29 July 2017

language of work or name

English

0 references

publication date

28 July 2009

1 reference

29 July 2017

1 reference

29 July 2017

volume

69

1 reference

29 July 2017

issue

15

1 reference

29 July 2017

page(s)

6208-6215

1 reference

Transcriptional inhibitors, p53 and apoptoss

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

A unique quinolineboronic acid-based supramolecular structure that relies on double intermolecular B-N bonds for self-assembly in solid state and in solution.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Cyclin-dependent kinase pathways as targets for cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Selectivity and potency of cyclin-dependent kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Secrets of a double agent: CDK7 in cell-cycle control and transcription

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Mammalian cyclin-dependent kinases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Living with or without cyclins and cyclin-dependent kinases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Minireview: Cyclin D1: normal and abnormal functions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Transcriptional signature of flavopiridol-induced tumor cell death.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

The use of CDK inhibitors in oncology: a pharmaceutical perspective

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Small-molecule cyclin-dependent kinase modulators

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Pharmacological inhibitors of cyclin-dependent kinases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

To cycle or not to cycle: a critical decision in cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

The role of Cdk7 in CAK function, a retro-retrospective

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Cyclin-dependent kinases: engines, clocks, and microprocessors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

The MO15 cell cycle kinase is associated with the TFIIH transcription-DNA repair factor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Association of Cdk-activating kinase subunits with transcription factor TFIIH

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

New colorimetric cytotoxicity assay for anticancer-drug screening

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2875168

Targeted inactivation of p53 in human cells does not result in aneuploidy

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19638587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19638587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19638587

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/0008-5472.CAN-09-0301

1 reference

29 July 2017

1 reference

29 July 2017

1 reference